GENOA 2 complement

Towards a blood test for the detection of breast cancer

Conducting RNASeq on PBMCs from patients recruited for the GENOA2 study. Specifically, we plan to sequence and analyse PBMCs from 20 healthy donors, 20 patients with primary breast cancer, 10 patients with colorectal cancer, 10 patients with lung cancer and 20 patients with inflammatory diseases. The healthy donors and patients with primary breast cancer will enable the extraction of an initial signature. Patients with colorectal and lung cancer, as well as those with inflammatory diseases, will allow us to fine-tune the signature to exclude other cancers and inflammatory diseases.
We anticipate that this important analysis, which is currently lacking, will help strengthen the results already achieved towards developing an effective blood test for clinical use.

This complementary study is funded by the Claudia von Schilling Foundation for Breast Cancer Research. Our sincere thanks go to this foundation.